Welcome to our dedicated page for KAIROS PHARMA SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kairos Pharma, Ltd. (KAPA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the NYSE American. These documents offer detailed information on its oncology programs, licensing arrangements, and corporate governance, and are an important resource for understanding how Kairos Pharma reports its activities to regulators and investors.
Through current reports on Form 8-K, Kairos Pharma has disclosed items such as equity compensation decisions, including grants of restricted stock units (RSUs) and cash bonuses to executives and directors under its equity incentive plan. These filings describe vesting terms, valuation references, and potential accelerated vesting upon a change in control, giving insight into the company’s approach to executive and board compensation.
Other 8-K filings outline material agreements and intellectual property arrangements. For example, Kairos Pharma has reported novation agreements that transferred exclusive license rights from its subsidiary Enviro Therapeutics, Inc. to the listed company, including licenses covering compositions and methods for treating diseases and conditions by depletion or detection of mitochondrial or genomic DNA from circulation and sensitization of tumors to therapies through endoglin (CD105) antagonism. A separate novation agreement with Tracon Pharmaceuticals, Inc. transferred Enviro’s rights and obligations under a license and supply agreement for TRC105 and CD105 technologies to Kairos.
Kairos Pharma also uses Form 8-K to furnish press releases and slide presentations related to its clinical programs, such as interim safety and efficacy data from the Phase 2 ENV105 trial in metastatic castration-resistant prostate cancer and initial Phase 1 data in non-small cell lung cancer. While these exhibits are furnished rather than filed for certain purposes, they provide additional context on the company’s CD105-targeted strategy and clinical development plans.
On Stock Titan, investors can view these filings as they are pulled from the SEC’s EDGAR system and use AI-powered summaries to interpret key points. The platform highlights major elements of Kairos Pharma’s disclosures, including clinical trial updates, licensing arrangements, compensation decisions, and other reported events, helping users navigate the technical language and understand how each filing relates to the company’s oncology pipeline and corporate structure.
Kairos Pharma, Ltd. has filed a shelf registration statement allowing it to offer up to $75,000,000 of common stock, preferred stock, debt securities, warrants and units over time. Within this, the company established an at‑the‑market equity program to sell up to $4,524,949 of common stock through H.C. Wainwright & Co. on the NYSE American.
Kairos is a clinical‑stage cancer drug developer with no approved products and no product revenue. It reported net losses of $4.1 million for the nine months ended September 30, 2025 and $2.6 million for 2024, with an accumulated deficit of about $12.9 million. As of January 12, 2026, public float was approximately $13,574,846, and the company is subject to limits that cap primary offerings under this registration at one‑third of its public float in any 12‑month period.
The filing details prior financing structures, including a $30 million equity line with Helena and a January 2025 PIPE that issued pre‑funded and common warrants, and explains that future proceeds from this shelf may support research and clinical development, working capital and other general corporate purposes.
Kairos Pharma, Ltd. reported an insider equity grant to its Chief Scientific Officer. On October 8, 2025, the officer acquired 171,756 restricted stock units (RSUs) of common stock at a price of $0.00 per share under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan.
The 171,756 RSUs are scheduled to vest on the first anniversary of the grant date, October 8, 2026. After this grant, the reporting person beneficially owns 1,311,739 shares, consisting of 1,135,317 shares of common stock and 176,422 RSUs that remain subject to vesting, all held as a direct ownership position.
Kairos Pharma, Ltd. director Hyun W. Bae reported equity awards and updated share ownership. On 09/16/2025, 10,000 restricted stock units (RSUs) of common stock were acquired at a price of $0.00, reflecting RSUs granted on September 16, 2024 in conjunction with the company’s initial public offering and scheduled to vest in three annual installments starting on the IPO anniversary. On 10/08/2025, an additional 19,084 RSUs were acquired at $0.00, which are scheduled to vest in full on the first anniversary of their grant date.
After these transactions, Bae beneficially owns 73,370 shares of common stock, consisting of 54,286 shares and 19,084 RSUs that remain subject to vesting, all held directly.
Kairos Pharma, Ltd. (KAPA) reported an equity award to its VP of Research and Development on a Form 4. On 10/08/2025, the officer acquired 152,672 restricted stock units (RSUs)$0.00 under the company’s 2023 Equity Incentive Plan. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, the officer beneficially owns 299,529 equity interests, consisting of 142,191 shares of common stock and 157,338 RSUs that remain subject to vesting. The filing indicates the holdings are owned directly.
Kairos Pharma, Ltd. (KAPA) reported equity awards to a director via a Form 4 filing. On 09/16/2025, the director acquired 10,000 shares of common stock at $0.00 per share, representing restricted stock units (RSUs) granted under the company’s 2023 Equity Incentive Plan in connection with its initial public offering. Following this grant, the director beneficially owned 10,000 shares, combining common stock and unvested RSUs.
On 10/08/2025, the director received an additional 19,084 RSUs at $0.00 per share under the same plan, which are scheduled to vest in full on the first anniversary of the grant date. After this transaction, the director beneficially owned 29,084 shares, consisting of 3,334 shares of common stock and 25,750 RSUs that remain subject to vesting.
Kairos Pharma, Ltd. (KAPA) reported an insider equity award on a Form 4. Director Rahul Singhvi received 19,084 restricted stock units (RSUs) of common stock on 10/08/2025 under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. These 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date and were recorded at a price of $0.00, reflecting that this is an equity award, not an open-market purchase.
Following this grant, Singhvi beneficially owns 49,204 RSUs, all of which remain subject to vesting conditions and are reported as directly held. The filing is made by a single reporting person in the capacity of director, and it documents non-derivative equity compensation rather than any sale of shares.
Kairos Pharma (KAPA) reported an equity award to its Chief Financial Officer, Doug Samuelson. On 10/08/2025, he received 152,672 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan at a price of $0.00 per share. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, Samuelson beneficially owns 293,039 common shares and RSUs in total, consisting of 140,367 shares of common stock and 152,672 RSUs that remain subject to vesting, all held in direct ownership.
Kairos Pharma (KAPA) reported an insider equity grant to its CEO and Chairman, John S. Yu, who is also a director and 10% owner. On 10/08/2025, he received 190,840 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan, with all 190,840 RSUs scheduled to vest on the first anniversary of the grant date. Following this award, he directly beneficially owns 230,105 shares of common stock, which consist of 34,599 shares and 195,506 RSUs that remain subject to vesting, and indirectly holds 5,316,572 shares through The Yu Family Trust, where he is trustee. This filing reflects equity-based compensation and confirms his significant ongoing ownership stake.
Kairos Pharma (KAPA)net loss of $1.4 million for the quarter and $4.1 million for the nine months ended September 30, 2025, with no revenue reported. Operating expenses rose as development advanced: R&D was $608k in Q3 ($1.6 million year‑to‑date) and G&A was $827k in Q3 ($2.6 million year‑to‑date).
Liquidity improved through 2025 financings. Cash and cash equivalents were $5.6 million and shareholders’ equity was $7.7 million at September 30, 2025. Year‑to‑date financing cash inflows included $3.1 million net from January pre‑funded units and $3.6 million from the equity line of credit. The company expects current cash to fund operations for at least 12 months from the filing date. Common shares outstanding were 20,821,353 as of November 14, 2025. Subsequent events include a $1.143 million Lonza agreement tied to ENV105 Phase 3 manufacturing preparation and new RSU grants for executives and directors.
FAQ
What is the current stock price of KAIROS PHARMA (KAPA)?
What is the market cap of KAIROS PHARMA (KAPA)?
